Key result
The EUTrigTreat prospective observational study is designed to evaluate novel electrophysiological and genetic risk markers for predicting all-cause mortality in 700 patients with an ICD indication.
Why the study?
Do novel and established risk markers, including repolarization biomarkers and genetics, predict all-cause mortality and ICD shock risk in patients with a clinical ICD indication?
Observational (n=700)
Yes
Do novel and established risk markers, including repolarization biomarkers and genetics, predict all-cause mortality and ICD shock risk in patients with a clinical ICD indication?
The EUTrigTreat study is designed to evaluate novel and established risk markers, including repolarization biomarkers and genetics, for predicting mortality and ICD shocks in patients with an ICD indication.
No takes yet. Share an insight, caveat, or question.
May identify novel markers for ICD risk stratification; leaves open clinical utility pending validation.
Seegers et al. (2011) conducted an observational in Patients with clinical ICD indication (n=700). Electrophysiological risk stratification and genetic screening was evaluated on All-cause mortality. The EUTrigTreat prospective observational study is designed to evaluate novel electrophysiological and genetic risk markers for predicting all-cause mortality in 700 patients with an ICD indication.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: